王宇昭,郑庆锋,吴楠,陈晋峰,冯源,王嘉,吕超,阎石,张力建,杨跃

• 1:北京大学临床肿瘤医院、北京肿瘤医院暨北京市肿瘤防治研究所胸外科二病区

摘要(Abstract)：

目的评价国产吉西他滨(誉捷)联合铂类方案治疗非小细胞肺癌的安全性及短期疗效。方法61例非小细胞肺癌患者采用誉捷+顺铂方案40例,誉捷+卡铂方案21例;化疗使用常规剂量及用法,每3周循环,至少完成2周期。以0~Ⅳ级记录化疗期间不良反应,化疗前及2周期后分别进行生活质量(QOL)评分,同时评估非手术患者化疗前后肿瘤大小变化。结果本组患者化疗后最主要的不良反应为白细胞下降、中性粒细胞下降和恶心呕吐,发生率分别为59.0%、41.0%和41.0%,其余不良反应发生率较低;中重度不良反应(Ⅲ+Ⅳ度)同样以白细胞下降、中性粒细胞下降和恶心呕吐为主,发生率分别为13.1%、14.8%和11.5%。全组患者化疗期间出现4例心脏相关事件,3例出血事件,1例患者出现中枢神经系统症状,经及时处理后患者均顺利出院。化疗后生活质量稳定和提高的患者占全组患者的68.9%;化疗前后患者生活质量分别为46.79±4.637和45.66±6.416,两者比较无统计学差异(P=0.312)。22例非手术患者化疗2周期后疗效为:10例SD,3例M R,8例PR,1例CR,治疗有效率(CR+PR)为40.9%。结论国产吉西他滨(誉捷)与铂类联合方案治疗非小细胞肺癌在用药安全性及短期疗效上与国外文献报道无明显差异,绝大多数患者能够良好耐受。

关键词(KeyWords)： 癌,非小细胞肺/药物疗法;肺肿瘤/药物疗法;顺铂/治疗应用;卡铂/治疗应用;药物疗法,联合;脱氧胞苷/类似物和衍生物;治疗结果

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王宇昭,郑庆锋,吴楠,陈晋峰,冯源,王嘉,吕超,阎石,张力建,杨跃

参考文献(References)：

• [1]Liao M,Zhu Y,Li L,et al.Gemcitabine and cisplatintreatment over a 3-weeek versus a 4-week dosingschedule:a randomized trial conducted in Chinesepatients with non-small cell lung cancer[J].Chin MedJ,2008,121(10):892-897.
• [2]Gridelli C,Shepherd FA.Chemotherapy for elderlypatients with non-small cell lung cancer:a review ofthe evidence[J].Chest,2005,128(2):947-957.
• [3]Rinaldi M,Cauchi C,Gridelli C.First linechemotherapy in advanced or metastatic NSCLC[J].Ann Oncol,2006,17(Suppl 5):64-67.
• [4]Ramalingam S,Belani C.Systemic chemotherapy foradvanced non-small cell lung cancer:recent advancesand future directions[J].Oncologist,2008,13(Suppl1):5-13.
• [5]Comella P,Gambardella A,Frasci G.Comparison ofthe safety and efficacy of paclitaxel plus gemcitabinecombination in young and elderly patients with locallyadvanced or metastatic non-small cell lung cancer:Aretrospective analysis of the Southern ItalyCooperative Oncology Group trials[J].Crit RevOncol Hematol,2008,65(2):164-171.
• [6]Kusaba H,Tamura T,Shimoyama T,et al.Phase/study of 3-week cycle cisplatin-gemcitabine inadvanced non-small cell lung cancer[J].Jpn J ClinOncol,2002,32(2):43-47.
• [7]Chen S,Lin MC,John WC,et al.Phase study ofregimen of gemcitabine and cisplatin in advanced non-small cell lung cancer.Jpn J Clin Oncol,2000,30(11):494-498.
• [8]Baliko Z,Sarosi V.The Hungarian experience withgemcitabine-cisplatin as first-line treatment ofadvanced non-small cell lung cancer:focus on safetyprofile[J].Lung Cancer,2003,41(S2):275.
• [9]Bunn PA,Kelly K.New chemotherapeutic agentsprolong survival and improve quality of life in non-small cell lung cancer:a review of the literature andfuture directions[J].Clin Cancer Res,1998,4(5):1087-1100.
• [10]Kosmidis P,Kalofonos H,Christodoulou C,et al.Paclitaxel and gemcitabine versus carboplatin andgemcitabine in patients with advanced non-small-celllung cancer.A phase study of the HellenicCooperative Oncology Group[J].Ann Oncol,2008,19(1):115-122.
• [11]Freitas J,Castro M,Valerio E,et al.Renalhypersensitivity and gastrointestinal toxicity relatedto gemcitabine/cisplatinum treatment in non-smallcell lung cancer[J].Eur J Cancer,2001,37(6):441.
• [12]Gallelli L,Nardi M,Prantera T,et al.Retrospectiveanalysis of adverse of drug reactions induced bygemcitabine treatment in patients with non-small celllung cancer[J].Pharm Res,2004,49(3):259-263.
• [13]Jidar K,Ingen-Housz-Oro S,Beylot-Barry M,et al.Gemcitabine treatment in cutaneous T-celllymphoma:a multicentre study of 23 cases[J].Br JDermatol,2009,160(3):660-663.
• [14]Gridelli C,Cigolari S,Gallo C,et al.Activity andtoxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancerelderly patients.Phase data from the MulticenterItalian Lung Cancer in the Elderly Study(MILES)randomized trial[J].Lung Cancer,2001,31(2):277-284.
• [15]Ferrari D,Carbone C,Codeca C,et al.Gemcitabineand atrial fibrillation:a rare manifestation ofchemotherapy toxicity[J].Anticancer Drugs,2006,17(3):359-361.
• [16]Munoz A,Mane JM,Rubio I,et al.Gemcitabine andvascular toxicity[J].Lung Cancer,2002,37(2):229.
• [17]Vander Els NJ,Miller V.Successful treatment ofgemcitabine toxicity with a brief course of oralcorticosteroid therapy[J].Chest,1998,114(6):1779-1781.
• [18]Pavlakis N,Bell DR,Millward MJ,et al.Fatalpulmonary toxicity resulting from treatment withgemcitabine[J].Cancer,1997,80(2):286-291.
• [19]Briasoulis E,Pavlidis N.Noncardiogenic pulmonaryedema:an unusual and serious complication ofanticancer therapy[J].Oncologist,2001,6(2):153-161.
• [20]Ciotti R,Belotti G,Facchi E,et al.Sudden cardio-pulmonary toxicity following a single infusion ofgemcitabine[J].Ann Oncol,1999,10(8):997-999.
• [21]Bdair FM,Graham SP,Smith PF,et al.Gemcitabineand acute myocardial infarction:a case report[J].Angiology,2006,57:367-370.
• [22]Numico G,Garrone O,Dongiovanni V,et al.Prospective evaluation of major vascular events inpatients with nonsmall cell lung carcinoma treatedwith cisplatin and gemcitabine[J].Cancer,2005,103(5):994-999.
• [23]Larsen FO,Hansen SW.Severe neurotoxicity causedby gemcitabine treatment[J].Acta Oncol,2004,43(6):590-591.
• [24]Rossi A,Gridelli C.Chemotherapy of advanced non-small cell lung cancer in elderly patients[J].AnnOncol,2006,17(2):58-60.